{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-024960","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.582753+00:00","generated_at":"2026-05-17T19:32:47.418561+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Moleculin preclin data: Annamycin shows efficacy in liver cancers; AML readout H2 2025","bullets":["Annamycin demonstrated anti-tumor activity in orthotopic HCC models, colorectal liver metastases, and PDAC liver metastases.","Preclinical data show targeted organ accumulation (liver, spleen, lungs, pancreas) vs doxorubicin; no cardiotoxicity seen.","Prior clinical data: 32 of 42 subjects received >FDA lifetime max anthracycline without cardiotoxicity.","Preliminary data readout for Annamycin in AML expected in second half of 2025.","Data presented at Shelby-Lavine Pancreatic Cancer Symposium at MD Anderson Cancer Center."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-024960","json":"https://secwatch.observer/filing/0001437749-25-024960.json","markdown":"https://secwatch.observer/filing/0001437749-25-024960.md","text":"https://secwatch.observer/filing/0001437749-25-024960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925024960/0001437749-25-024960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925024960/mbrx20250805_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:32:47.418561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}